M&A / Deals Biogen to acquire RayThera for up to $1bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. Neuroscience Read full story Post navigation Previous: FDA experts endorse Moderna’s mRNA seasonal flu shotNext: US launches probe of German ‘underpayment’ for medicines Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026